Biotech | March 10, 2022
Gufic Biosciences collaborates with Selvax for cancer treatment
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Neural sleeve first algorithm-powered bionic garment designed to help those with mobility issues due to multiple sclerosis, stroke, cerebral palsy, and other conditions, regain functional movement in everyday activities
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Subscribe To Our Newsletter & Stay Updated
